This presentation contains estimates and other statistical data prepared by independent parties and by Neuronetics, Inc. (the “Company”) relating to market size and growth and other data about the industry in which the Company operates. These estimates and data involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates and data.

Certain statements in this presentation and the accompanying oral commentary are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements, including statements relating to the Company's business strategy and financial metrics as well as revenue, operating expense and earnings guidance and projections for future periods, relate to future events or the future financial performance of the Company and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “potential” or other comparable terminology, as well as the negative of such statements. All statements other than statements of historical fact may be deemed to be forward-looking statements, including those concerning any expectations regarding investment returns; any projections of financial information; any statements about historical results that may suggest trends for our business; any statements of the plans, strategies, and objectives of management for future operations; any statements of expectation or belief regarding future events, potential markets or market size, additional indications or technology developments; developments in clinical trials or regulatory review of NeuroStar® Advanced Therapy System for additional indications; and any statements of assumptions underlying any of the items mentioned. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company’s control. These and other important factors may cause actual results, performance or achievements to differ materially from those expressed or implied by such forward-looking statements. The forward-looking statements in this presentation are made only as of the date hereof. Except as required by law, the Company assumes no obligation and does not intend to update these forward-looking statements or to conform these statements to actual results or to changes in the Company’s expectations, assumptions, estimates and projections.
Our Mission: Renewing Lives by Transforming Neurohealth

NeuroStar Advanced Therapy for Mental Health

**Indication**
Adults with Major Depressive Disorder (MDD) who have not benefited from antidepressant medication (17.3 million US adults)

**Market Leader**
Market leader in TMS for depression with over 4 million treatment sessions and over 110,000 patients treated

**Sales & Customer Support**
Largest direct sales and customer support team in the industry

**Reimbursement**
Broad US reimbursement among commercial and government payors

**Clinical Dataset**
Largest clinical dataset in TMS for depression

**Outcomes Registry**
Largest depression outcomes registry in the world

**Indications & Growth**
New indication opportunities and geographic expansion for growth
Patients with Major Depressive Disorder are Underserved

The medical industry has relied on pharmaceuticals as the first line treatment for MDD

3 out of 5 patients treated with medication are underserved

MDD is a leading cause of disability and a major contributor to suicide worldwide*

300 million people worldwide living with depression

- 3.0% incidence rate

Economic burden in US of $210 billion annually

*Source: https://www.who.int/news-room/fact-sheets/detail/depression

Current Solution: Antidepressant Medications

- Lack of Efficacy
- Intolerable Side Effects

US Adults suffering from MDD

17.3 MILLION

Patients with MDD being treated

11.2 MILLION

Poorly served

6.2 MILLION

1. https://www.nimh.nih.gov/health/statistics/major-depression.shtml, accessed 4/28/2021 | 2. Per STAR*D patients that have failed one or more antidepressant trial of adequate dose and duration
The largest prospective clinical trial of MDD ever conducted, STAR*D, showed that treatment resistance causes a patient’s chance for remission to decrease with each subsequent medication attempt.

STAR*D also showed discontinuation due to side effects increases with each treatment attempt.
NeuroStar Delivers Proven Results

83% Response and 62% Remission for patients

Clinically Proven Durability Established Over 12 Months

Long-term post-acute treatment\(^1\)

Only NeuroStar has…

\[\begin{array}{c|c|c|c|c}
                  & END OF ACUTE & 3 Months & 6 Months & 9 Months & AFTER 12 MONTHS \\
\hline
\textcolor{purple}{\text{Response (CGI-S≤3)}} & 62.3        & 41.2     & 66.1     & 44.4     & 67.7%   \\
\textcolor{lightblue}{\text{Remission (CGI-S≤2)}} & 62.3        & 43.2     & 68.1     & 47.5     & 45.1%   \\
\end{array}\]

Safety Record

- 4 million+ treatment sessions delivered globally
- Over 110,000 patients treated
- Low discontinuation rate from adverse events ~5%\(^1\)

Investigator-initiated Trials

- More than 65 studies with over 1,900 patients
- Wide range of conditions, including anxiety, bipolar disorder, pain, PTSD, addiction, schizophrenia, tinnitus, and others

Only NeuroStar has...

Substantial Body of Clinical Evidence

Unmatched Body of Clinical Data for TMS in Depression

15 Studies >1,000 Patients Resulting in 28 Publications

1. In sham-controlled studies
Only NeuroStar has...

Patented Contact Sensing Technology
Consistent and Repeatable Treatment

• The smallest movements can result in a dramatic loss of the prescribed TMS dose
• Even 1 mm movement away from the head can result in 40% loss of the TMS prescribed dose
• Continuous contact sensing solves this problem

1mm is the equivalent of 3 grains of salt

Contact Sensing

• Constantly monitors patient contact with the NeuroStar coil and alerts the clinician if the coil loses contact with the scalp or is angled incorrectly

Good Contact
Bad Contact

• Only NeuroStar Advanced Therapy provides real-time feedback about the coil’s angle and contact
Only NeuroStar has...

Proprietary TrakStar® Data Management System

TrakStar makes automated large-scale data collection feasible

>110,000
Total NeuroStar patients treated worldwide

>64,000
US patients completing ≥20 treatments

World’s Largest Depression Outcomes Registry

>11,999
Total Outcomes Registry patients

2 Outcomes Registry Peer-reviewed Publications\(^1,^2\)

---

Only NeuroStar has...

Invested in Understanding the Market

67% of patients with MDD are unhappy with their current treatment

Based on market research study of 500 diagnosed depression patients

67%

Two Distinct Groups

**Struggling Independents**

NO LONGER TRUST THEIR PHYSICIAN
– will seek out other doctor for new treatment

**Challenged Optimists**

WILLING TO ASK THEIR PHYSICIAN ABOUT NEUROSTAR

Patients Are Looking for New Treatment Solutions

“Just okay is not okay…”

“I’ve lost hope…”

“There’s got to be something more…”

“I’m going to keep fighting…”

WILLING TO ASK THEIR PHYSICIAN ABOUT NEUROSTAR
27 Drop-out Points in the Patient Journey

Only NeuroStar has developed the 5-STARS to Success Program to address drop-out points.
NeuroStar Program

Precision Pulse Program

Co-op Marketing

MyNeuroStar.com

And other benefits designed to help NeuroStar practices build awareness and improve NeuroStar access for patients
# Largest Direct Sales and Customer Support Team

<table>
<thead>
<tr>
<th>Role</th>
<th>Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>NeuroStar Practice Consultants</td>
<td>29</td>
</tr>
<tr>
<td>Business Development Managers</td>
<td>22</td>
</tr>
<tr>
<td>Field Service and Technical Support</td>
<td>17</td>
</tr>
<tr>
<td>Sales Leaders</td>
<td>12</td>
</tr>
<tr>
<td>Clinical Training Consultants</td>
<td>8</td>
</tr>
<tr>
<td>Reimbursement Specialists and Managers</td>
<td>7</td>
</tr>
<tr>
<td>Customer Service Representatives</td>
<td>6</td>
</tr>
<tr>
<td>Inside Sales Representatives</td>
<td>4</td>
</tr>
</tbody>
</table>
Offered by the Largest National Providers in the Country

- greenbrook gb
- SuccessTMS
- Southern California TMS Center
- Elite DNA Therapy Services
- LifeStance Heath
- Transformations
- ZC TMS
- REFRESH Mental Health
- ACTIVE RECOVERY TMS
<table>
<thead>
<tr>
<th>CPT Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>90867</td>
<td>MT Assist and Treatment Session</td>
</tr>
<tr>
<td>90868</td>
<td>Treatment Session</td>
</tr>
<tr>
<td>90869</td>
<td>Subsequent MT Assist and Treatment Session</td>
</tr>
</tbody>
</table>

**Widely Reimbursed**

**95% Coverage**
Estimated to cover 95% of total private payor covered lives in the US

**Top 25 US Private Insurers**
95+ major US private insurers provide coverage policies representing 300 million covered lives

**100% Medicare Coverage**
61 million covered lives
Economics

Physician Practices

Proven return on investment for physicians

Meaningful incremental income potential for physician practice

Recoup capital investment by treating ~12 patients

Generate ~$8,500 average revenue per patient per course of treatment

Conclusion: 1 patient per month can equal $100,000 in practice revenue

NeuroStar Advanced Therapy for Mental Health has potential to enhance physician practice economics
# Competitive Positioning

<table>
<thead>
<tr>
<th>Feature</th>
<th>NeuroStar</th>
<th>BrainsWay</th>
<th>Magstim</th>
<th>MagVenture</th>
<th>Mag &amp; More</th>
<th>CLOUD TMS</th>
<th>Nexstim</th>
<th>NeuroStar</th>
</tr>
</thead>
<tbody>
<tr>
<td>Practice Consultants</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>$10M Marketing including DTC Advertising</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FDA-cleared for iTBS Theta Burst</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Contact Sensing</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>World’s Largest MDD Outcomes Registry</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Publications from Depression Registration Trials</td>
<td>12</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1. TouchStar w/Contact Sensing

**Legend:**
- ✓: Available
- -: Not Available
Japan Roadmap

• Primary international focus is on Japan
• Third largest healthcare spend globally
• Single payor healthcare system
• Shonin approval
• Exclusive distribution agreement with Teijin Pharma
• Reimbursement

Estimated TAM in Japan for Treatment Sessions

• Adults Suffering from MDD 2.4 million
• Treated by a Psychiatrist 655,000
• Failed to achieve remission 475,000
• ~$600 Million Addressable Market
Large issued patent portfolio of all TMS companies, protecting our technical advantage and ensuring freedom to operate globally

**Patent Portfolio**

- **41 US / 54 OUS**
  - Issued or allowed patents
- **5 US / 8 OUS**
  - Pending patent applications

**Contact Sensing**

Multiple U.S. patents

**MT Assist**

U.S. patent

**Iron Core Magnet**

Multiple U.S. patents
The NeuroStar Difference

**PROOF**
Over 12 years as market leader

**ONLY NEUROSTAR HAS...**
- The world’s largest depression Outcomes Registry
- Proven long term durability
- Contact Sensing
- TrakStar® – manage/track/report
- TouchStar – theta burst
- 28 Publications including 12 in depression registration trials

**PEOPLE**
Team dedicated to your practice success

**ONLY NEUROSTAR PROVIDES...**
- More than 100 team members dedicated to growing NeuroStar practices
- Lifetime support with strength in numbers
- On-site service within 24 hours for non-operational NeuroStar Systems

**PROGRAMS**
Driving market awareness to grow your practice

**ONLY NEUROSTAR WILL SPEND $10+ MILLION IN MARKETING IN 2021 AND HAS...**
- 5-STARS to Success Program
- Precision Pulse Program
- Co-op Marketing
- Stellar Distinctions
Management Team

- Rob Cascella
  Board Chairman
- John Bakewell
- Sheryl Conley
- Wilfred Jaeger
- Keith Sullivan
  President & CEO
- Cory Anderson
  VP Clinical Affairs & Interim VP R&D
- Todd Cushman
  VP Business Development
- Steve Furlong
  SVP CFO & Treasurer
- Keith Sullivan
  President & CEO
- Cory Anderson
  VP Clinical Affairs & Interim VP R&D
- Todd Cushman
  VP Business Development
- Steve Furlong
  SVP CFO & Treasurer
- Rick Grubbs
  VP National Accounts
- Sara Grubbs
  VP Sales
- Andrew Macan
  SVP General Counsel
- Claire Sears
  VP Marketing
- Kara Thornton
  VP Human Resources

Board of Directors

- Rob Cascella
  Board Chairman
- John Bakewell
- Sheryl Conley
- Wilfred Jaeger
- Keith Sullivan
  President & CEO
- Cory Anderson
  VP Clinical Affairs & Interim VP R&D
- Todd Cushman
  VP Business Development
- Steve Furlong
  SVP CFO & Treasurer
- Rick Grubbs
  VP National Accounts
- Sara Grubbs
  VP Sales
- Andrew Macan
  SVP General Counsel
- Claire Sears
  VP Marketing
- Kara Thornton
  VP Human Resources

- Glenn Muir
- Megan Rosengarten
- Bruce Shook
- Keith Sullivan
  President & CEO
- Cory Anderson
  VP Clinical Affairs & Interim VP R&D
- Todd Cushman
  VP Business Development
- Steve Furlong
  SVP CFO & Treasurer
- Rick Grubbs
  VP National Accounts
- Sara Grubbs
  VP Sales
- Andrew Macan
  SVP General Counsel
- Claire Sears
  VP Marketing
- Kara Thornton
  VP Human Resources
- Glenn Muir
  SVP General Counsel
- Megan Rosengarten
  VP Human Resources
- Bruce Shook
  President & CEO
- Keith Sullivan
  President & CEO
Financial Overview

NeuroStar Advanced Therapy for Mental Health
Annual Revenue

Annual Revenue by Geography

- 2018: $52.8, $1.3
- 2019: $62.7, $1.9
- 2020: $49.2, $1.7
- Guidance: $59.0-$63.0

Annual Product Revenue (US)

- 2018: $51.5
- 2019: $60.8
- 2020: $47.5

NeuroStar Systems
- 2018: $35.3
- 2019: $41.1
- 2020: $34.9

Treatment Sessions
- 2018: $14.6
- 2019: $18.0
- 2020: $11.1

Other
- 2018: $0
- 2019: $1.6
- 2020: $1.6

($ in millions)
Worldwide Quarterly Revenue

Q2 2021 Revenue of $14.2M was up 46% from Q2 2020

($ in millions)
# Results of Operations

<table>
<thead>
<tr>
<th>($ in thousands)</th>
<th>Three Months Ended June 30,</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2020</td>
</tr>
<tr>
<td><strong>Revenues</strong></td>
<td>$9,741</td>
</tr>
<tr>
<td><strong>YOY Growth</strong></td>
<td>46%</td>
</tr>
<tr>
<td><strong>Gross Profit</strong></td>
<td>7,418</td>
</tr>
<tr>
<td><strong>Gross Margin</strong></td>
<td>76%</td>
</tr>
<tr>
<td><strong>Operating Expenses:</strong></td>
<td></td>
</tr>
<tr>
<td>Sales and Marketing</td>
<td>8,151</td>
</tr>
<tr>
<td>% of Revenues</td>
<td>84%</td>
</tr>
<tr>
<td>General and Administrative</td>
<td>4,010</td>
</tr>
<tr>
<td>% of Revenues</td>
<td>41%</td>
</tr>
<tr>
<td>Research and Development</td>
<td>2,116</td>
</tr>
<tr>
<td>% of Revenues</td>
<td>22%</td>
</tr>
<tr>
<td><strong>Total Operating Expenses</strong></td>
<td>14,277</td>
</tr>
<tr>
<td><strong>Loss from Operations</strong></td>
<td>($6,859)</td>
</tr>
<tr>
<td>% of Revenues</td>
<td>-70%</td>
</tr>
</tbody>
</table>
# Financial Position

<table>
<thead>
<tr>
<th>($ in thousands)</th>
<th>As of June 30, 2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and Cash Equivalents</td>
<td>$115,783</td>
</tr>
<tr>
<td>Other Assets</td>
<td>$32,315</td>
</tr>
<tr>
<td><strong>Total Assets</strong></td>
<td><strong>$148,098</strong></td>
</tr>
<tr>
<td>Long-term Debt, net</td>
<td>$34,944</td>
</tr>
<tr>
<td>Convertible Preferred Stock Warrant Liability</td>
<td>$0</td>
</tr>
<tr>
<td>Convertible Preferred Stock</td>
<td>$0</td>
</tr>
<tr>
<td>Accumulated Deficit</td>
<td>($292,946)</td>
</tr>
<tr>
<td><strong>Total Stockholders’ Equity</strong></td>
<td><strong>$97,166</strong></td>
</tr>
</tbody>
</table>
Supplemental Information

NeuroStar Advanced Therapy for Mental Health
### U.S. NeuroStar Revenue

<table>
<thead>
<tr>
<th>NeuroStar REVENUE</th>
<th>Q1-19</th>
<th>Q2-19</th>
<th>Q3-19</th>
<th>Q4-19</th>
<th>Q1-20</th>
<th>Q2-20</th>
<th>Q3-20</th>
<th>Q4-20</th>
<th>Q1-21</th>
<th>Q2-21</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total U.S. NeuroStar Revenue ($000)</td>
<td>$3,350</td>
<td>$4,628</td>
<td>$4,616</td>
<td>$5,413</td>
<td>$2,594</td>
<td>$2,338</td>
<td>$2,541</td>
<td>$3,620</td>
<td>$1,755</td>
<td>$2,577</td>
</tr>
<tr>
<td>YoY ↑</td>
<td>41%</td>
<td>30%</td>
<td>18%</td>
<td>14%</td>
<td>-23%</td>
<td>-49%</td>
<td>-45%</td>
<td>-33%</td>
<td>-32%</td>
<td>10%</td>
</tr>
<tr>
<td>U.S. NeuroStar Capital Revenue ($000) (1)</td>
<td>$2,939</td>
<td>$4,034</td>
<td>$4,264</td>
<td>$4,959</td>
<td>$2,410</td>
<td>$2,224</td>
<td>$2,438</td>
<td>$3,446</td>
<td>$1,589</td>
<td>$2,441</td>
</tr>
<tr>
<td>YoY ↑</td>
<td>54%</td>
<td>23%</td>
<td>24%</td>
<td>14%</td>
<td>-18%</td>
<td>-45%</td>
<td>-43%</td>
<td>-31%</td>
<td>-34%</td>
<td>10%</td>
</tr>
<tr>
<td>U.S. NeuroStar Operating Lease Revenue ($000) (2)</td>
<td>$182</td>
<td>$187</td>
<td>$184</td>
<td>$177</td>
<td>$155</td>
<td>$114</td>
<td>$88</td>
<td>$79</td>
<td>$108</td>
<td>$55</td>
</tr>
<tr>
<td>YoY ↑</td>
<td>-29%</td>
<td>3%</td>
<td>-31%</td>
<td>-24%</td>
<td>-15%</td>
<td>-39%</td>
<td>-52%</td>
<td>-55%</td>
<td>-30%</td>
<td>-51%</td>
</tr>
<tr>
<td>U.S. NeuroStar Other ($000) (3)</td>
<td>$229</td>
<td>$407</td>
<td>$167</td>
<td>$278</td>
<td>$29</td>
<td>$0</td>
<td>$15</td>
<td>$96</td>
<td>$58</td>
<td>$81</td>
</tr>
<tr>
<td>YoY ↑</td>
<td>11%</td>
<td>239%</td>
<td>-21%</td>
<td>50%</td>
<td>-87%</td>
<td>-100%</td>
<td>-91%</td>
<td>-66%</td>
<td>100%</td>
<td>100%</td>
</tr>
</tbody>
</table>

(1) = Revenue includes NeuroStar System Capital Sales and Sales Type Leases
(2) = Revenue derived from Operating Lease revenue amortization during the period
(3) = Revenue derived from Treatment Coils in U.S.
## U.S. NeuroStar Treatment Sessions

<table>
<thead>
<tr>
<th>Total U.S. Treatment Session Revenues ($000)</th>
<th>Q1-19</th>
<th>Q2-19</th>
<th>Q3-19</th>
<th>Q4-19</th>
<th>Q1-20</th>
<th>Q2-20</th>
<th>Q3-20</th>
<th>Q4-20</th>
<th>Q1-21</th>
<th>Q2-21</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>$8,778</td>
<td>$10,847</td>
<td>$10,252</td>
<td>$11,243</td>
<td>$8,193</td>
<td>$6,547</td>
<td>$9,083</td>
<td>$11,029</td>
<td>$9,629</td>
<td>$10,801</td>
</tr>
<tr>
<td>YoY D</td>
<td>21%</td>
<td>22%</td>
<td>11%</td>
<td>13%</td>
<td>-7%</td>
<td>-40%</td>
<td>-11%</td>
<td>-2%</td>
<td>18%</td>
<td>65%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Average Revenue per Active Site ($000) (1)</th>
<th>$12.4</th>
<th>$14.7</th>
<th>$13.2</th>
<th>$13.5</th>
<th>$9.4</th>
<th>$7.4</th>
<th>$10.2</th>
<th>$12.1</th>
<th>$10.5</th>
<th>$12.0</th>
</tr>
</thead>
<tbody>
<tr>
<td>YoY D</td>
<td>NM</td>
<td>1%</td>
<td>-9%</td>
<td>-8%</td>
<td>-24%</td>
<td>-50%</td>
<td>-22%</td>
<td>-10%</td>
<td>12%</td>
<td>62%</td>
</tr>
</tbody>
</table>

(1) = Total Treatment Session Revenue / Active Sites (Ending of Prior Quarter)
### Supplemental Financial and Operating Information

#### Revenue ($ thousands)

<table>
<thead>
<tr>
<th></th>
<th>2019</th>
<th>2020</th>
<th>2021</th>
<th>2020</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>NeuroStar Capital (1)</strong></td>
<td>$2,939</td>
<td>$4,034</td>
<td>$2,410</td>
<td>$2,224</td>
</tr>
<tr>
<td>YoY Change</td>
<td>54%</td>
<td>29%</td>
<td>14%</td>
<td>-18%</td>
</tr>
<tr>
<td><strong>YoY Change</strong></td>
<td></td>
<td></td>
<td></td>
<td>-34%</td>
</tr>
<tr>
<td><strong>NeuroStar Operating Lease (2)</strong></td>
<td>$182</td>
<td>$187</td>
<td>$155</td>
<td>$114</td>
</tr>
<tr>
<td>YoY Change</td>
<td>-29%</td>
<td>3%</td>
<td>-15%</td>
<td>-39%</td>
</tr>
<tr>
<td><strong>YoY Change</strong></td>
<td></td>
<td></td>
<td></td>
<td>-31%</td>
</tr>
<tr>
<td><strong>Other (3)</strong></td>
<td>$229</td>
<td>$407</td>
<td>$29</td>
<td>$0</td>
</tr>
<tr>
<td>YoY Change</td>
<td>11%</td>
<td>239%</td>
<td>-87%</td>
<td>-100%</td>
</tr>
<tr>
<td><strong>YoY Change</strong></td>
<td></td>
<td></td>
<td></td>
<td>-100%</td>
</tr>
<tr>
<td><strong>Total U.S. NeuroStar Advanced Therapy System Revenues</strong></td>
<td>$3,350</td>
<td>$4,626</td>
<td>$2,594</td>
<td>$2,338</td>
</tr>
<tr>
<td>YoY Change</td>
<td>41%</td>
<td>30%</td>
<td>-23%</td>
<td>-49%</td>
</tr>
<tr>
<td><strong>YoY Change</strong></td>
<td></td>
<td></td>
<td></td>
<td>-33%</td>
</tr>
<tr>
<td><strong>Total U.S. Treatment Sessions Revenues</strong></td>
<td>$8,778</td>
<td>$10,847</td>
<td>$8,193</td>
<td>$6,547</td>
</tr>
<tr>
<td>YoY Change</td>
<td>21%</td>
<td>22%</td>
<td>-7%</td>
<td>-40%</td>
</tr>
<tr>
<td><strong>YoY Change</strong></td>
<td></td>
<td></td>
<td></td>
<td>-11%</td>
</tr>
<tr>
<td><strong>Total U.S. Other Revenues</strong></td>
<td>$418</td>
<td>$415</td>
<td>$390</td>
<td>$382</td>
</tr>
<tr>
<td>YoY Change</td>
<td>16%</td>
<td>1%</td>
<td>-7%</td>
<td>-8%</td>
</tr>
<tr>
<td><strong>YoY Change</strong></td>
<td></td>
<td></td>
<td></td>
<td>-5%</td>
</tr>
<tr>
<td><strong>Total U.S. Revenues</strong></td>
<td>$12,546</td>
<td>$15,890</td>
<td>$11,177</td>
<td>$9,267</td>
</tr>
<tr>
<td>YoY Change</td>
<td>26%</td>
<td>23%</td>
<td>-11%</td>
<td>-42%</td>
</tr>
<tr>
<td><strong>YoY Change</strong></td>
<td></td>
<td></td>
<td></td>
<td>-21%</td>
</tr>
<tr>
<td><strong>Total International Revenues</strong></td>
<td>$182</td>
<td>$682</td>
<td>$299</td>
<td>$474</td>
</tr>
<tr>
<td>YoY Change</td>
<td>1%</td>
<td>90%</td>
<td>64%</td>
<td>-31%</td>
</tr>
<tr>
<td><strong>YoY Change</strong></td>
<td></td>
<td></td>
<td></td>
<td>-41%</td>
</tr>
<tr>
<td><strong>Total Revenues</strong></td>
<td>$12,728</td>
<td>$16,572</td>
<td>$12,476</td>
<td>$9,741</td>
</tr>
<tr>
<td>YoY Change</td>
<td>25%</td>
<td>25%</td>
<td>-10%</td>
<td>-41%</td>
</tr>
<tr>
<td><strong>YoY Change</strong></td>
<td></td>
<td></td>
<td></td>
<td>-22%</td>
</tr>
</tbody>
</table>

#### Average Revenue Per Active Site ($)

<table>
<thead>
<tr>
<th></th>
<th>2019</th>
<th>2020</th>
<th>2021</th>
<th>2020</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Average Revenue Per Active Site</strong></td>
<td>$12,415</td>
<td>$14,718</td>
<td>$9,418</td>
<td>$7,406</td>
</tr>
<tr>
<td>YoY Change</td>
<td>79%</td>
<td>42%</td>
<td>-12%</td>
<td>-43%</td>
</tr>
<tr>
<td><strong>YoY Change</strong></td>
<td></td>
<td></td>
<td></td>
<td>-33%</td>
</tr>
</tbody>
</table>

#### U.S. Operating and Financial Metrics

<table>
<thead>
<tr>
<th></th>
<th>2019</th>
<th>2020</th>
<th>2021</th>
<th>2020</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total NeuroStar Systems Sold (4)</strong></td>
<td>43</td>
<td>61</td>
<td>38</td>
<td>35</td>
</tr>
<tr>
<td>YoY Change</td>
<td>79%</td>
<td>42%</td>
<td>-12%</td>
<td>-43%</td>
</tr>
<tr>
<td><strong>YoY Change</strong></td>
<td></td>
<td></td>
<td></td>
<td>-33%</td>
</tr>
</tbody>
</table>

#### Total U.S. Revenues

<table>
<thead>
<tr>
<th></th>
<th>2019</th>
<th>2020</th>
<th>2021</th>
<th>2020</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total U.S. Revenues</strong></td>
<td>$12,728</td>
<td>$16,572</td>
<td>$12,476</td>
<td>$9,741</td>
</tr>
<tr>
<td>YoY Change</td>
<td>25%</td>
<td>25%</td>
<td>-10%</td>
<td>-41%</td>
</tr>
<tr>
<td><strong>YoY Change</strong></td>
<td></td>
<td></td>
<td></td>
<td>-22%</td>
</tr>
</tbody>
</table>

#### YoY Change

- Revenue from Capital Sales and Sales Type Leases
- Revenue derived from Operating Lease revenue during the period
- Primarily includes revenue derived from Treatment Coils in US
- Includes all systems sold during the period, both as Capital Sales or Sales Type Leases
- Total U.S. Treatment Session Revenue / Active Sites (End of Prior Period)